With a market cap of $28.1 billion, San Diego, California-based ResMed Inc. (RMD) develops and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders worldwide. The company operates through two segments: Sleep and Breathing Health, and Residential Care Software, offering solutions ranging from sleep diagnostics and therapy devices to comprehensive healthcare software platforms.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and ResMed fits this criterion perfectly. Its innovations include portable diagnostic tools, cloud-based monitoring systems, and enterprise software solutions supporting sleep clinics, home medical equipment providers, and senior care organizations.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Shares of the medical products maker have fallen 12.7% from its 52-week high of $293.81. RMD stock has declined 21.7% over the past three months, lagging behind the Dow Jones Industrials Average's ($DOWI) 4.6% rise over the same time frame.
www.barchart.com RMD stock is down 19.6% on a YTD basis, underperforming the DOWI’s 3.9% gain. In the longer term, shares of the medical device maker have decreased 23.4% over the past 52 weeks, compared to DOWI's 16.5% return over the same time frame.
Despite a few fluctuations, the stock has been trading below its 200-day moving average since November 2025.
www.barchart.com ResMed reported fiscal Q3 2026 results on Apr. 30 that exceeded Wall Street expectations, with adjusted EPS of $2.86 and revenue rising 11% year over year to $1.43 billion, driven by strong demand for its sleep apnea and respiratory care devices. The company also stated that GLP-1 weight-loss drugs could help bring more patients into the sleep apnea treatment market, as increased awareness and medical consultations may lead to greater adoption of ResMed’s therapies and devices. However, the stock fell 4.1% the next day.
In comparison, ResMed stock has underperformed its rival, Becton, Dickinson and Company (BDX). BDX stock has gained 7.8% over the past 52 weeks and dropped 3.1% on a YTD basis.
Despite RMD’s underperformance, analysts remain moderately optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 20 analysts covering it, and the mean price target of $264.92 is a premium of 36.9% to current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Nvidia Chose This AI Cloud Stock Over Everyone Else. Here’s Why. 1 Verizon Insider Sells 80% of Her Stock in $3 Million Deal. For Everyone Else, VZ Is a Good Buy Now. AMD Stock Could Surge Past $665 on Explosive Data Center Demand Bearish Setups Alert: June 11th Bear Put Spread Scan Results